Fewer than 30% of health system leaders said they earned significant return on investment from virtual care offerings, ...
Drugs that will be subject to rebates in 340B next year include Bristol Myers Squibb’s Eliquis, Johnson & Johnson’s Stelara ...
Former Congressional Budget Office Director Dan Crippen argues the 340B discount program is overdue for reform.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback